arXiv subjects

Bowen Gao

Publications and source records attributed to Bowen Gao.

At least 19 recordsLinked to original sources

arXiv2026

PharmAgents2: Towards Autonomous End-to-End Drug Discovery

Drug discovery requires continuous scientific decision-making across a vast research space. We introduce PharmAgents2, an autonomous system for end-to-end drug discovery that combines knowledge-enhanced decision-making with organized large-scale exploration. Paper2Skill extracts transferable scientific decision knowledge from public sources and, together with expert-developed skills, supports research decisions. Self-Scaling Discovery expands exploration through parallel agents inheriting research context and decision-making capabilities across targets, scientific hypotheses, and discovery strategies. We introduce PharmAgents-Bench v0.1, comprising 121 questions across nine decision scenarios and three end-to-end tasks assessed with expert-defined process rubrics. PharmAgents2 outperforms evaluated baselines in most decision categories and achieves the highest process scores on all three end-to-end tasks. In three real-world studies, autonomous investigations generated findings subsequently supported by human-executed experiments. For LpxH, PharmAgents2 hypothesized a previously unreported allosteric site and screened compounds against it, identifying a novel inhibitor scaffold with experimentally confirmed inhibitory activity and binding. For JAK1, it prioritized a covalent inhibition strategy and nominated compounds with experimentally demonstrated activity. Starting from a known bioactive molecule, Self-Scaling Discovery explored candidate targets across the proteome and identified a new binding target, with the interaction subsequently confirmed experimentally. PharmAgents2 represents a prototype of a virtual pharmaceutical company, marking a step toward autonomous end-to-end drug discovery.

cs.AI↗

arXiv2026

From MS/MS evidence to adaptive spectroscopic characterization: Reinforcement learning guided by candidate molecular structures

Small-molecule identification from tandem mass spectrometry (MS/MS) may require complementary measurements. Herein, we propose a structure-informed deep Q-network (SI-DQN) that uses existing MS/MS evidence to decide whether further characterization is needed, which measurement to request, and when to stop. The policy combines spectral representations and candidate rankings with score-weighted descriptors of the candidates' chemical features and structural differences. The policy was evaluated on 79,462 held-out samples with simulated MS/MS, infrared (IR), and nuclear magnetic resonance (NMR) spectra from the Multimodal Spectroscopic Dataset. Evaluation used fixed hard candidate sets containing the correct structure and equal normalized acquisition costs. Averaged across three training runs, SI-DQN increased Top-1 accuracy from 80.10% to 93.78% for positive-ion MS/MS starts and from 70.44% to 93.31% for negative-ion starts. The corresponding mean additional measurement counts were only 0.227 and 0.340 per sample, respectively. Complete acquisition achieved 97.72% accuracy with four additions, whereas SI-DQN reduced the additional measurement count by 94.3% and 91.5%. Relative to a rule-based policy, SI-DQN reduced the composite loss combining terminal ranking error and acquisition cost by 19.3% and 25.5%. Adding structural information to DQN further improved accuracy while reducing requests across all three training runs. At comparable ranking uncertainty, SI-DQN increased request rates relative to DQN more strongly in groups with high structural disagreement, where larger reductions in composite loss were also observed. Together, these results support using the ambiguity among candidate structures after MS/MS analysis to guide further characterization, providing a quantitative basis for balancing identification performance against subsequent measurement effort.

cs.LG↗

arXiv2026

Coder as Editor: Code-driven Interpretable Molecular Editing

Molecular design is a central task in drug discovery that requires precise structural reasoning and domain knowledge. While large language models (LLMs) have shown promise in generating high-level editing intentions in natural language, they often struggle to faithfully execute these modifications, particularly when operating on non-intuitive representations like SMILES. We introduce MECo, a framework that bridges reasoning and execution by translating editing actions into executable code. MECo reformulates molecular modification for LLMs as a cascaded framework: generating human-interpretable editing intentions from a molecule and design objective, followed by translating those intentions into executable structural edits via code generation. Our approach achieves over 98% accuracy in reproducing held-out realistic edits derived from chemical reactions and target-specific compound pairs. On downstream benchmarks spanning physicochemical properties and target activities, MECo substantially improves consistency by 38-86 percentage points to 90%+ and achieves higher success rates over SMILES-based baselines while preserving structural similarity. By aligning intention with execution, MECo enables consistent, controllable and interpretable molecular design, laying the foundation for high-fidelity feedback loops and collaborative human-AI workflows in drug discovery.

cs.LG↗

arXiv2026

Generative Retrieval for Reverse Target Fishing with a Proteome-Scale Benchmark

Reverse target fishing identifies protein targets for a query molecule and is central to drug discovery and repurposing. Discriminative approaches adapted from virtual screening face sparse, long-tailed associations and missing-not-at-random measurements: treating unrecorded pairs as negatives can suppress genuine targets. We reformulate the task as generative retrieval and introduce GenFish. Residual vector quantization converts frozen protein language model features into shared semantic identifiers. Given a molecular fingerprint, GenFish autoregressively models codes conditioned on the query and preceding code, ranking proteins by identifier likelihood without explicitly labeling unrecorded pairs as negatives. We introduce ProTargetBench, the first proteome-scale benchmark for reverse target fishing to jointly support measured-panel discrimination and full-catalogue recovery of experimentally recorded positives. Covering 20,431 UniProt-reviewed human proteins, it integrates curated bioactivity evidence and distinguishes experimental inactivity from unmeasured associations. On 198 held-out molecules, GenFish achieves higher mean performance across all three full-catalogue retrieval metrics than four discriminative neural baselines and three non-neural baselines, including ligand-based methods. A controlled positive-hiding experiment shows that targeted removal of false-negative competition improves contrastive retrieval beyond matched random masking; GenFish remains stronger under the same incomplete supervision. Pfam alignment indicates that the semantic identifiers capture biologically meaningful relationships among proteins. These results establish generative retrieval as a principled paradigm for reverse target fishing under incomplete bioactivity records.

cs.LG↗

arXiv2026

EBRL: Asynchronous Embodied RL by Multi-Grained Resource Management

Embodied reinforcement learning (RL) improves model capabilities with a pipeline of environment simulation, action generation, and model updates. These stages show heterogeneous CPU and GPU demands, making efficient resource utilization difficult. Recent systems overlap rollout (simulation and generation) with training for efficiency, but exclusive GPU allocation and synchronized barrier in rollout still leave substantial hardware resource waste. In this paper, we present EBRL, an asynchronous embodied RL training system with two core techniques. The asynchronous pipelined scheduler overlaps rollout and training, pipelines simulation and generation across environment groups, and carries out each environment independently, eliminating synchronization stalls. The fine-grained resource manager pools CPU cores and GPU streaming multiprocessors, and uses stage profiles and runtime feedback to adjust resource quotas and batch sizes to meet the shifting demands among stages. We implement EBRL on RLinf and evaluate it with four embodied policies and four simulation benchmarks across heterogeneous GPU testbeds. Experiments show that EBRL achieves 1.30-3.47 times the end-to-end rollout throughput and 2.5 times of training convergency compared to the SOTA embodied RL systems.

cs.LG↗

arXiv2026

Robust small-molecule identification from incomplete, degraded, and inconsistent spectra using multimodal mixed-condition training

Reliable small-molecule identification often requires complementary evidence from multiple spectroscopic measurements. In practice, however, spectra may be unavailable, degraded by measurement-related variations, or even incorrectly associated with a sample, thereby hindering accurate molecular identification. Herein, we propose a multimodal mixed-condition training strategy that accommodates missing, degraded, and mismatched measurements for small-molecule structure identification. The strategy incorporates chemical and spectroscopic knowledge through predefined missing-input configurations, modality-specific spectral perturbations, and chemically informed spectrum replacements. Models were trained on 635,441 samples comprising mass spectrometry (MS), infrared (IR), and nuclear magnetic resonance (NMR) simulated spectra from the Multimodal Spectroscopic Dataset (MSSD). They were then systematically evaluated on 79,462 held-out samples across 30 views designed to represent variations in spectra. A controlled comparison of complete-input and mixed-condition training under concatenation and mixture-of-experts (MoE) fusion showed that the training strategy was the principal source of improvement. For MoE, mixed-condition training increased the mean reciprocal rank (MRR) by 6.08% (from 0.9203 to 0.9763) and the top-1 molecular identification rate by 7.67% (from 89.50% to 96.36%). Notably, under single-modality inputs, IR MRR increased 2.15-fold (from 0.4337 to 0.9307), while MS MRR increased 2.31-fold (from 0.3711 to 0.8575). With the proposed strategy, complete-input performance remained high, while sample-level mismatch detection also improved. Together, these results highlight the potential of multimodal mixed-condition training for practical molecular identification by explicitly addressing incomplete, degraded, and mismatched measurements encountered in real-world analysis.

cs.LG↗

arXiv2026

A mixed precision algorithm for the matrix square root

Mixed precision algorithms can significantly enhance the performance of linear algebra solvers by leveraging increasingly powerful low precision hardware while recovering working precision accuracy through, for example, iterative refinement. In this paper, we propose a novel mixed precision algorithm for computing matrix square roots. Our algorithm combines a Schur decomposition approach in low precision with iterative refinement performed through an approximate Newton method. We perform a detailed convergence analysis of the approximate Newton method. For the special case of symmetric positive definite matrices, this analysis implies that one can recover full working precision accuracy under mild conditions. Numerical experiments on x86-64 architectures indicate that our algorithm frequently reduces execution time compared with a fixed working-precision Schur algorithm.

math.NA↗

arXiv2025

Learning Protein-Ligand Binding in Hyperbolic Space

Protein-ligand binding prediction is central to virtual screening and affinity ranking, two fundamental tasks in drug discovery. While recent retrieval-based methods embed ligands and protein pockets into Euclidean space for similarity-based search, the geometry of Euclidean embeddings often fails to capture the hierarchical structure and fine-grained affinity variations intrinsic to molecular interactions. In this work, we propose HypSeek, a hyperbolic representation learning framework that embeds ligands, protein pockets, and sequences into Lorentz-model hyperbolic space. By leveraging the exponential geometry and negative curvature of hyperbolic space, HypSeek enables expressive, affinity-sensitive embeddings that can effectively model both global activity and subtle functional differences-particularly in challenging cases such as activity cliffs, where structurally similar ligands exhibit large affinity gaps. Our mode unifies virtual screening and affinity ranking in a single framework, introducing a protein-guided three-tower architecture to enhance representational structure. HypSeek improves early enrichment in virtual screening on DUD-E from 42.63 to 51.44 (+20.7%) and affinity ranking correlation on JACS from 0.5774 to 0.7239 (+25.4%), demonstrating the benefits of hyperbolic geometry across both tasks and highlighting its potential as a powerful inductive bias for protein-ligand modeling.

cs.LG↗

arXiv2025

S$^2$Drug: Bridging Protein Sequence and 3D Structure in Contrastive Representation Learning for Virtual Screening

Virtual screening (VS) is an essential task in drug discovery, focusing on the identification of small-molecule ligands that bind to specific protein pockets. Existing deep learning methods, from early regression models to recent contrastive learning approaches, primarily rely on structural data while overlooking protein sequences, which are more accessible and can enhance generalizability. However, directly integrating protein sequences poses challenges due to the redundancy and noise in large-scale protein-ligand datasets. To address these limitations, we propose \textbf{S$^2$Drug}, a two-stage framework that explicitly incorporates protein \textbf{S}equence information and 3D \textbf{S}tructure context in protein-ligand contrastive representation learning. In the first stage, we perform protein sequence pretraining on ChemBL using an ESM2-based backbone, combined with a tailored data sampling strategy to reduce redundancy and noise on both protein and ligand sides. In the second stage, we fine-tune on PDBBind by fusing sequence and structure information through a residue-level gating module, while introducing an auxiliary binding site prediction task. This auxiliary task guides the model to accurately localize binding residues within the protein sequence and capture their 3D spatial arrangement, thereby refining protein-ligand matching. Across multiple benchmarks, S$^2$Drug consistently improves virtual screening performance and achieves strong results on binding site prediction, demonstrating the value of bridging sequence and structure in contrastive learning.

cs.LG↗

arXiv2025

AANet: Virtual Screening under Structural Uncertainty via Alignment and Aggregation

Virtual screening (VS) is a critical component of modern drug discovery, yet most existing methods--whether physics-based or deep learning-based--are developed around holo protein structures with known ligand-bound pockets. Consequently, their performance degrades significantly on apo or predicted structures such as those from AlphaFold2, which are more representative of real-world early-stage drug discovery, where pocket information is often missing. In this paper, we introduce an alignment-and-aggregation framework to enable accurate virtual screening under structural uncertainty. Our method comprises two core components: (1) a tri-modal contrastive learning module that aligns representations of the ligand, the holo pocket, and cavities detected from structures, thereby enhancing robustness to pocket localization error; and (2) a cross-attention based adapter for dynamically aggregating candidate binding sites, enabling the model to learn from activity data even without precise pocket annotations. We evaluated our method on a newly curated benchmark of apo structures, where it significantly outperforms state-of-the-art methods in blind apo setting, improving the early enrichment factor (EF1%) from 11.75 to 37.19. Notably, it also maintains strong performance on holo structures. These results demonstrate the promise of our approach in advancing first-in-class drug discovery, particularly in scenarios lacking experimentally resolved protein-ligand complexes. Our implementation is publicly available at https://github.com/Wiley-Z/AANet.

cs.LG↗

arXiv2025

Mixed precision iterative refinement for least squares with linear equality constraints and generalized least squares problems

Recent development on mixed precision techniques has largely enhanced the performance of various linear algebra solvers, one of which being the solver for the least squares problem $\min_{x}\lVert b-Ax\rVert_{2}$. By transforming least squares problems into augmented linear systems, mixed precision techniques are capable of refining the lower precision solution to the working precision. In this paper, we propose mixed precision iterative refinement algorithms for two variants of least squares problems -- the least squares problem with linear equality constraints (LSE) and the generalized least squares problem (GLS). Both classical and GMRES-based iterative refinement can be applied to augmented systems of these two problems to improve the accuracy of the solution. For reasonably well-conditioned problems, our algorithms reduce the execution time by a factor of 40% on average compared to the fixed precision ones from LAPACK on the x86-64 architecture.

math.NA↗

arXiv2025

PharmAgents: Building a Virtual Pharma with Large Language Model Agents

The discovery of novel small molecule drugs remains a critical scientific challenge with far-reaching implications for treating diseases and advancing human health. Traditional drug development--especially for small molecule therapeutics--is a highly complex, resource-intensive, and time-consuming process that requires multidisciplinary collaboration. Recent breakthroughs in artificial intelligence (AI), particularly the rise of large language models (LLMs), present a transformative opportunity to streamline and accelerate this process. In this paper, we introduce PharmAgents, a virtual pharmaceutical ecosystem driven by LLM-based multi-agent collaboration. PharmAgents simulates the full drug discovery workflow--from target discovery to preclinical evaluation--by integrating explainable, LLM-driven agents equipped with specialized machine learning models and computational tools. Through structured knowledge exchange and automated optimization, PharmAgents identifies potential therapeutic targets, discovers promising lead compounds, enhances binding affinity and key molecular properties, and performs in silico analyses of toxicity and synthetic feasibility. Additionally, the system supports interpretability, agent interaction, and self-evolvement, enabling it to refine future drug designs based on prior experience. By showcasing the potential of LLM-powered multi-agent systems in drug discovery, this work establishes a new paradigm for autonomous, explainable, and scalable pharmaceutical research, with future extensions toward comprehensive drug lifecycle management.

q-bio.BM↗

arXiv2025

Pushing the boundaries of Structure-Based Drug Design through Collaboration with Large Language Models

Structure-Based Drug Design (SBDD) has revolutionized drug discovery by enabling the rational design of molecules for specific protein targets. Despite significant advancements in improving docking scores, advanced 3D-SBDD generative models still face challenges in producing drug-like candidates that meet medicinal chemistry standards and pharmacokinetic requirements. These limitations arise from their inherent focus on molecular interactions, often neglecting critical aspects of drug-likeness. To address these shortcomings, we introduce the Collaborative Intelligence Drug Design (CIDD) framework, which combines the structural precision of 3D-SBDD models with the chemical reasoning capabilities of large language models (LLMs). CIDD begins by generating supporting molecules with 3D-SBDD models and then refines these molecules through LLM-supported modules to enhance drug-likeness and structural reasonability. When evaluated on the CrossDocked2020 dataset, CIDD achieved a remarkable success ratio of 37.94%, significantly outperforming the previous state-of-the-art benchmark of 15.72%. Although improving molecular interactions and drug-likeness is often seen as a trade-off, CIDD uniquely achieves a balanced improvement in both by leveraging the complementary strengths of different models, offering a robust and innovative pathway for designing therapeutically promising drug candidates.

q-bio.BM↗

arXiv2024

SIU: A Million-Scale Structural Small Molecule-Protein Interaction Dataset for Unbiased Bioactivity Prediction

Small molecules play a pivotal role in modern medicine, and scrutinizing their interactions with protein targets is essential for the discovery and development of novel, life-saving therapeutics. The term "bioactivity" encompasses various biological effects resulting from these interactions, including both binding and functional responses. The magnitude of bioactivity dictates the therapeutic or toxic pharmacological outcomes of small molecules, rendering accurate bioactivity prediction crucial for the development of safe and effective drugs. However, existing structural datasets of small molecule-protein interactions are often limited in scale and lack systematically organized bioactivity labels, thereby impeding our understanding of these interactions and precise bioactivity prediction. In this study, we introduce a comprehensive dataset of small molecule-protein interactions, consisting of over a million binding structures, each annotated with real biological activity labels. This dataset is designed to facilitate unbiased bioactivity prediction. We evaluated several classical models on this dataset, and the results demonstrate that the task of unbiased bioactivity prediction is challenging yet essential.

q-bio.BM↗

arXiv2024

From Theory to Therapy: Reframing SBDD Model Evaluation via Practical Metrics

Recent advancements in structure-based drug design (SBDD) have significantly enhanced the efficiency and precision of drug discovery by generating molecules tailored to bind specific protein pockets. Despite these technological strides, their practical application in real-world drug development remains challenging due to the complexities of synthesizing and testing these molecules. The reliability of the Vina docking score, the current standard for assessing binding abilities, is increasingly questioned due to its susceptibility to overfitting. To address these limitations, we propose a comprehensive evaluation framework that includes assessing the similarity of generated molecules to known active compounds, introducing a virtual screening-based metric for practical deployment capabilities, and re-evaluating binding affinity more rigorously. Our experiments reveal that while current SBDD models achieve high Vina scores, they fall short in practical usability metrics, highlighting a significant gap between theoretical predictions and real-world applicability. Our proposed metrics and dataset aim to bridge this gap, enhancing the practical applicability of future SBDD models and aligning them more closely with the needs of pharmaceutical research and development.

q-bio.BM↗

arXiv2024

Multi-level Interaction Modeling for Protein Mutational Effect Prediction

Protein-protein interactions are central mediators in many biological processes. Accurately predicting the effects of mutations on interactions is crucial for guiding the modulation of these interactions, thereby playing a significant role in therapeutic development and drug discovery. Mutations generally affect interactions hierarchically across three levels: mutated residues exhibit different sidechain conformations, which lead to changes in the backbone conformation, eventually affecting the binding affinity between proteins. However, existing methods typically focus only on sidechain-level interaction modeling, resulting in suboptimal predictions. In this work, we propose a self-supervised multi-level pre-training framework, ProMIM, to fully capture all three levels of interactions with well-designed pretraining objectives. Experiments show ProMIM outperforms all the baselines on the standard benchmark, especially on mutations where significant changes in backbone conformations may occur. In addition, leading results from zero-shot evaluations for SARS-CoV-2 mutational effect prediction and antibody optimization underscore the potential of ProMIM as a powerful next-generation tool for developing novel therapeutic approaches and new drugs.

cs.LG↗

arXiv2024

ProFSA: Self-supervised Pocket Pretraining via Protein Fragment-Surroundings Alignment

Pocket representations play a vital role in various biomedical applications, such as druggability estimation, ligand affinity prediction, and de novo drug design. While existing geometric features and pretrained representations have demonstrated promising results, they usually treat pockets independent of ligands, neglecting the fundamental interactions between them. However, the limited pocket-ligand complex structures available in the PDB database (less than 100 thousand non-redundant pairs) hampers large-scale pretraining endeavors for interaction modeling. To address this constraint, we propose a novel pocket pretraining approach that leverages knowledge from high-resolution atomic protein structures, assisted by highly effective pretrained small molecule representations. By segmenting protein structures into drug-like fragments and their corresponding pockets, we obtain a reasonable simulation of ligand-receptor interactions, resulting in the generation of over 5 million complexes. Subsequently, the pocket encoder is trained in a contrastive manner to align with the representation of pseudo-ligand furnished by some pretrained small molecule encoders. Our method, named ProFSA, achieves state-of-the-art performance across various tasks, including pocket druggability prediction, pocket matching, and ligand binding affinity prediction. Notably, ProFSA surpasses other pretraining methods by a substantial margin. Moreover, our work opens up a new avenue for mitigating the scarcity of protein-ligand complex data through the utilization of high-quality and diverse protein structure databases.

cs.LG↗

arXiv2024

Rethinking Specificity in SBDD: Leveraging Delta Score and Energy-Guided Diffusion

In the field of Structure-based Drug Design (SBDD), deep learning-based generative models have achieved outstanding performance in terms of docking score. However, further study shows that the existing molecular generative methods and docking scores both have lacked consideration in terms of specificity, which means that generated molecules bind to almost every protein pocket with high affinity. To address this, we introduce the Delta Score, a new metric for evaluating the specificity of molecular binding. To further incorporate this insight for generation, we develop an innovative energy-guided approach using contrastive learning, with active compounds as decoys, to direct generative models toward creating molecules with high specificity. Our empirical results show that this method not only enhances the delta score but also maintains or improves traditional docking scores, successfully bridging the gap between SBDD and real-world needs.

q-bio.BM↗